NUCLIDIUM Closes CHF 79 Million (EUR 84 Million) Series B Financing to Advance Clinical Development of its Copper-based Radiopharmaceutical Platform

Proceeds will fund further clinical development of the company's true theranostic pipeline and expansion of the global production and manufacturing network for copper-based radiopharmaceuticals.

Initial clinical data presented at SNMMI 2025 by Dr. Gary Ulaner, MD, PhD show a solid safety profile and potentially improved performance of 61Cu-NuriPro in metastatic prostate cancer imaging.

The financing round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Eurazeo, Vives Partners, NRW.BANK and HighLight Capital, with existing investors.

Alongside Tony Rosenberg, who recently joined as the Chairman of the Board of Directors, David Meek joins as an additional new Independent Director; Oliver Sartor, MD and Bela Denes, MD join as additional Scientific Advisors.

Basel, Switzerland / Munich, Germany, July 10, 2025, NUCLIDIUM AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based theranostic platform, today announced the successful closing of its Series B financing round, raising CHF 79 million (EUR 84 million). The round was led by Kurma Growth Opportunities Fund, Angelini Ventures, Wellington Partners, and Neva SGR (Intesa Sanpaolo Group), with participation from DeepTech & Climate Fonds (DTCF), Bayern Kapital, Vives Partners, Eurazeo, NRW.BANK and HighLight Capital, as well as existing investors. The proceeds will be used to advance the clinical development of NUCLIDIUM's Copper-61/Copper-67 (61Cu/67Cu) theranostic pipeline across multiple oncology indications. In parallel, the company will expand its production and manufacturing capabilities through a global production network.